# Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

> **NCT02769520** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Assuntina G. Sacco, MD** · enrollment: 27 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02769520
- **Lead sponsor:** Assuntina G. Sacco, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-06
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769520, "Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02769520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*